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Approximately 1% of the general population in western industrialized countries suffers
from vestibular migraine. However, it remains widely unknown and often under diagnosed
despite the recently published diagnostic criteria for vestibular migraine. Treatment trials
that specialize on vestibular migraine are scarce and systematic randomized controlled
clinical trials are now only emerging. This review summarizes the knowledge on the cur-
rently available treatment options that were tested specifically for vestibular migraine and
gives an evidence-based, informed treatment recommendation with all its limitations. To
date only two randomized controlled treatment trials provide limited evidence for the use
of rizatriptan and zolmitriptan for the treatment of vestibular migraine attacks because
of methodological shortcomings. There is an ongoing multicenter randomized placebo-
controlled trial testing metoprolol 95 mg vs. placebo (PROVEMIG-trial). Therefore, the
therapeutic recommendations for the prophylactic treatment of vestibular migraine are
currently widely based on the guidelines of migraine with and without aura as well as
expert opinion.
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INTRODUCTION
Dizziness and headache are frequently reported symptoms in clin-
ical neurology (1, 2). About 30–50% of all patients with migraine
describe vertigo or dizziness associated with their migraine at least
occasionally (3, 4). The International Headache Society (IHS),
the Bárány-Society (International Society for Neuro-Otology),
otorhinolaryngologists, and other scientists have created a con-
sensus document with consistent diagnostic criteria for vestibular
migraine (5, 6) that was considered in the appendix of the new
ICHD-3 beta version of the international headache classification
(7). These internationally accepted diagnostic criteria are intended
to further promote the systematic research on vestibular migraine
including clinical trials. Furthermore, they serve to create more
certainty in diagnostic assessment and clinical management of
these patients in everyday clinical practice. It remains an ongoing
discussion whether vestibular migraine is an autonomous disor-
der with distinct pathophysiological features or whether it simply
represents a subform of migraine that also includes vestibular
symptoms (8).
Approximately two-thirds of the patients experience vertigo or
dizziness seek professional medical care because of their symp-
toms, but only in 20% of all patients vestibular migraine was
diagnosed (9). The various interpretations by different specialties
regarding the combination of both symptoms, i.e., headache and
vertigo, are alarming. A survey among neurologists and otologists
reports that neurologists would diagnose a vestibular migraine
in 82% of patients with vertigo and headache, while this opin-
ion was shared only by 64.5% of ENT physicians. Surprisingly,
in the context of this survey 19% of ENT physicians and even
14.5% of neurologists declared never to have treated a patient
with vestibular migraine before (9).
Treatment trials that specifically address vestibular migraine
are scarce and most treatment suggestions for vestibular migraine
are extrapolated from knowledge gathered from clinical trials on
migraine with and without aura. This review summarizes the
current knowledge about treatment options that are specific for
vestibular migraine.
METHODS
A Medline search was conducted to collect all available pub-
lished data on the treatment of vestibular migraine. The search
terms vestibular AND migraine returned 427 publications includ-
ing 115 review articles and 18 labeled as clinical trial (October
2014). The combination of “vestibular migraine” returned 115
publications including two labeled as clinical trials and 37 as
review articles. Overall, 22 publications were related to the specific
treatment of vestibular migraine, not considering the numerous
reviews about vestibular migraine and not considering the evi-
dence rating. Some patients enrolled in these trials did not fulfill
the later defined diagnostic criteria for vestibular migraine and in
some, a different terminology was used. The most common terms
to describe the combination of both (migraine and vestibular
symptoms) besides vestibular migraine (10) were migrainous ver-
tigo, migraine-associated vertigo, vertiginous migraine, migraine-
associated balance disturbance, and benign paroxysmal vertigo.
BURDEN OF VESTIBULAR MIGRAINE
In population-based studies the lifetime prevalence of migraine
and vertigo in the general population of Germany as a repre-
sentative of the western industrial nations was approximately
16 and 7%, respectively (1, 11). In the general population, the
lifetime prevalence of vestibular migraine was 1%, with a one-year
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prevalence of 0.9% (12). A large epidemiological study showed the
concurrent presence of both symptoms in 3.2% of all patients (1).
A different survey described the presence of dizziness or vertigo in
47.5% of patients with migraine during a severe migraine attack
with pain intensity of 7 or more on a visual analog scale (VAS
0= no pain, 10=worst imaginable pain) (13).
Vestibular migraine can occur in any period of life (10, 14, 15).
Women are affected more frequently than men with a gender ratio
between 1.5 and 5 (10, 15–17). A familial clustering as well as
an autosomal-dominant inheritance with a lower penetrance in
males was described (18). In most patients, vestibular migraine
appears in an advanced period of life and often with a temporal
delay to the first onset of migraine (10, 17). The association of
vestibular symptoms with migraine with aura is controversial, as
some studies found this connection (10, 17, 19–22), while others
discovered that patients with migraine without aura have vestibu-
lar symptoms more often or at least equally often as migraine with
aura patients (10, 16, 19). In elderly patients, especially in post-
menopausal women, the typical migraine attacks are sometimes
replaced by isolated episodes of vertigo, dizziness, or transient
feeling of disequilibrium (23).
CLINICAL PRESENTATION
In a large population-based survey the most frequent vertigo
symptoms were a spontaneous rotatory vertigo in 67% followed by
positional vertigo in 24% of patients with vestibular migraine (12).
Initial spontaneous rotatory vertigo can turn into a positional or
illusion of movement type vertigo with gait disturbances (24, 25).
An increased sensitivity to motion, particularly to movements of
the head, or fast-moving visual objects are often part of the attack
(26, 27).
The duration of attacks vary from few seconds (10% of
patients) to some minutes (30% of patients), some hours (30%
of patients), and even up to a few days (30% of patients) (10, 14,
16, 19). Only 10–30% of patients report a typical vestibular aura
with duration between 5 and 60 min (10, 17). Approximately 30%
of all vestibular migraine attacks are not accompanied by headache
(14, 16, 17). In these cases, the typical migraine-associated symp-
toms like phono-/photophobia, osmophobia, nausea and vomit-
ing, aggravation by movement, or the need to rest are the crucial
symptoms for diagnosis (28). Gaze-induced nystagmus, saccadic
pursuit (especially vertically), central positional nystagmus, and
a slight horizontal or vertical spontaneous nystagmus can be
observed during or after a migraine attack and might support
the diagnosis (10).
BASILAR-TYPE MIGRAINE
Basilar-type migraine, in contrast to vestibular migraine, was
already defined in the ICHD-2 classification and can be distin-
guished clearly from vestibular migraine in most cases (28). In
the revised ICHD-3 beta classification, it is termed migraine with
brainstem aura (7). Less than 10% of patients with vestibular
migraine meet the diagnostic criteria for basilar-type migraine
(16, 17). By definition, basilar-type migraine requires at least two
aura symptoms, which are assignable to the vertebrobasilar terri-
tory, which last between 5 and 60 min, and which are followed by a
typical migraine headache (28). The extent to which both kinds of
migraine can be distinguished and to what degree there are over-
laps in some patients or disease constellations remains subject of
current research.
MEDICAL THERAPY
There are two randomized controlled clinical studies on the spe-
cific treatment of vestibular migraine with triptans (29, 30). This
study suggested a benefit from zolmitriptan 5 mg in 38% (three
of eight episodes) of patients with vestibular migraine attacks,
whereas in the placebo group a positive effect was observed
in only 22% (two of nine episodes). Unfortunately, the valid-
ity of this study is limited due to the large confidence intervals
and the small number of patients recruited (n= 10) with only
17 reported attacks (29). A double-blind, randomized, placebo-
controlled study with rizatriptan vs. placebo measured motion
sickness in response to a complex vestibular stimulus. Subjects
included 25 migraineurs with or without migraine-related dizzi-
ness (23 females) aged 21–45 years (31.0± 7.8 years). Results indi-
cated that of the 15 subjects who experienced vestibular-induced
motion sickness 13 showed a decrease in motion sickness after
rizatriptan compared to placebo (p< 0.02). However, this positive
effect was not seen after exposure to more provocative vestibular
stimulation. It was suggested by the authors that the serotonin ago-
nist, rizatriptan, reduces vestibular-induced motion sickness by
influencing serotonergic vestibular-autonomic projections (30).
All other therapeutic approaches are based on case reports, ret-
rospective cohort studies, and open-label trials (Table 1). Many
therapeutic recommendations for vestibular migraine are cur-
rently based on the guidelines of migraine with and without aura.
This is supported by a large retrospective cohort evaluation on
100 patients (median age 47 years, range 21–72 years) that com-
pared vestibular migraine patients with and without prophylactic
migraine treatment (31). All patients on prophylactic treatment
showed a decrease of duration, intensity, and frequency of episodic
vertigo as well as its associated features (p< 0.01). Medications
used were beta-blocker [49 patients, metoprolol (69%; median
dose 150 mg) or propranolol (31%; median dose 160 mg)], val-
proic acid (6 patients, 8%; median dose 600 mg), topiramate 6
patients (8%; median dose 50 mg), butterbur extract 4 patients
(5%; median dose 50 mg), lamotrigine 3 patients (4%; median
dose 75 mg), amitriptyline (2 patients; 100 and 75 mg), flunar-
izine (1 patient: 5 mg), and magnesium (3 patients; median dose
400 mg). The group without prophylactic therapy showed a reduc-
tion of vertigo intensity only (31). A different retrospective study
with 100 patients also indicated a positive effect of migraine pro-
phylactic medication in patients with vestibular migraine (32). In
the third retrospective cohort study, 33 patients with recurrent
vertiginous attacks and migraine were evaluated. The assessment
of frequency reduction showed complete disappearance in 19
patients (57.6%), over 50% reduction in 8 (24.2%), under 50%
reduction in 5 (15.2%), and no reduction in one patient. Propra-
nolol was used by 12 patients, metoprolol by 2, flunarizine by 7,
amitriptyline by 2, and clonazepam by 11 patients (33).
Drugs intended for acute treatment such as sumatriptan, non-
steroidal anti-inflammatory drugs (NSAID), and ergots as well
as preventive migraine medications such as beta blockers, tri-
cyclic antidepressants, methysergide, flunarizine, topiramate, and
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Table 1 |Treatment options in vestibular migraine.
Acute
treatment
Dosage Trial (Reference)
Zolmitriptan 2.5 mg oral Randomized controlled trial (RCT) (29)
Rizatriptan 10 mg oral RCT, motion sickness (30)
PROPHYLACTICTREATMENT
Metoprolol 150 mg oral Retrospective cohort analysis (31)
100–200 mg oral Retrospective cohort analysis (33)
Propranolol 160 mg oral Retrospective cohort analysis (31)
40–160 mg oral Retrospective cohort analysis (32, 33)
Valproic acid 600 mg oral Retrospective cohort analysis (31)
600 mg oral Cohort study, vestibulo-ocluar reflex (34)
Topiramate 50 mg oral Retrospective cohort analysis (31)
50–100 mg oral Open-label, chart review (44)
Butterbur
extract
50 mg oral Retrospective cohort analysis (31)
Lamotrigine 75 mg oral Retrospective cohort analysis (31)
100 mg oral Retrospective, open-label (41)
Amitriptyline 100 mg oral Retrospective cohort analysis (31)
10 mg oral Retrospective cohort analysis (33)
Nortriptyline 25–75 mg oral Open-label, chart review (44)
Flunarizine 5 mg oral Retrospective cohort analysis (31)
5–10 mg oral Retrospective, open-label (33)
5–10 mg Open-label, post-marketing (36, 37)
Magnesium 400 mg oral Retrospective cohort analysis (31)
Clonazepam 0,25–1 mg oral Retrospective cohort analysis (33)
Cinnarizine 37.5–75 mg oral Retrospective, open-label (35)
NON-MEDICALTREATMENT
Vestibular
rehabilitation
exercises
5 therapy
sessions over
9 weeks
Uncontrolled, observational trial (43)
Caffeine
cessation
4–6 weeks Retrospective, observational trial (44)
valproate were studied (33). In a different study, sodium valproate
did not relief vestibular symptoms but did have a considerable
effect on migraine headache in 8 of 12 patients (34). In this
study, the horizontal vestibulo-ocular reflex (VOR) was evalu-
ated by sinusoidal harmonic acceleration test at 0.01, 0.02, 0.04,
0.08, and 0.16 Hz using a computerized rotatory chair system. No
abnormalities were found for the VOR gain, phase and asymmetry
for any frequency. These normal VOR measurements contrasted
with the repeated complaints of dizziness, vertigo and unsteadi-
ness reported by seven patients (58%) that remained unchanged
by valproate treatment (34).
Cinnarizine was tested in a retrospective, single-center, open-
label, investigation of the effects of cinnarizine on vestibular
migraine and migraine associated with vertigo (35). The study
included 24 subjects with VM (23 women, 1 man) and 16 sub-
jects with basilar type Migraine (12 women, 4 men). The ages of
subjects ranged from 18 to 54 years (mean 30 years). The mean
frequency of vertigo and also the mean frequency, duration and
intensity of migraine headaches per month were reduced signif-
icantly after three months of cinnarizine therapy (all p< 0.001)
(35). This will have to be reconfirmed in a large scale, randomized,
controlled clinical trial.
There are two large open-label post-marketing studies investi-
gating flunarizine for the treatment of migraine and the treatment
of vertigo (36, 37). In both conditions, flunarizine showed consid-
erable efficacy compared to propranolol for migraine or betahis-
tine for vertigo. Unfortunately, both studies did not look at patients
that suffered from migraine and vertigo specifically and thus the
effect of flunarizine can be suspected, but remains unproven. One
randomized control trial (RCT) was undertaken in a tertiary aca-
demic center in order to evaluate the efficacy of flunarizine in
48 patients with vestibular migraine over 12 weeks in compari-
son to treatment with betahistine 16 mg and vestibular exercises
(38). The frequency of vertiginous episodes decreased with flunar-
izine treatment (p= 0.010) and severity of vertigo also improved
(p= 0.046). Headache frequency and severity was not signifi-
cantly different between treatment groups. The main side effects
were weight gain and somnolence (38). A different retrospective
chart study evaluated the effect of flunarizine and propranolol
on vestibular migraine patients. Thirty patients with flunarizine
showed a 68% responder rate of VM symptoms (p< 0.001). For
propranolol, 31 patients showed an improvement of symptoms in
73% (p< 0.001) (39).
Lamotrigine was reported to be effective in the treatment of
migraine auras, isolated auras, and to a lesser extend migraine-
associated headaches (40). One retrospective, open-label study
investigated the efficacy of 100 mg lamotrigine in 19 patients (6
men, 13 women) with vestibular migraine over 3–4 months. The
average vertigo frequency per month was reduced from 18.1 to
5.4, headache frequency dropped from 8.7 to 4.4, but did not
reach statistical significance. Therefore, lamotrigine appears to
mainly act on vestibular symptoms and only to a lesser extent
on headaches (41). Lamotrigine was also effective in three patients
with basilar-type migraine over five years (42).
Less conventional drugs such as benzodiazepines, selective sero-
tonin reuptake inhibitors (SSRI), pizotifen, dothiepin, and aceta-
zolamide, as well as behavioral modification such as special diets
were reported to have a positive effect on vestibular migraine (33).
However, it is difficult to extract a clear therapeutic recommen-
dation for the particular treatment of vestibular migraine from
these data. Furthermore, it must be kept in mind that inconsis-
tent definitions of vestibular migraine were used in the context of
these studies. As a result, the examined patient groups were quite
heterogenous. In the future, this deficit should be eliminated by
the new diagnostic criteria, hopefully leading to more comparable,
high quality studies.
NON-MEDICAL TREATMENT OPTIONS
Vestibular rehabilitation exercises were described to be beneficial
in patients with vestibular migraine in addition to medical treat-
ment or as stand alone treatment option (43). Thirty-six patients
(vestibular migraine= 20, vestibular impairment= 16) with daily
vestibular symptoms received a 9 week vestibular rehabilitation
program. Each subject attended five therapy appointments at ini-
tial, 2, 5, 9, and 6 months. While the vestibular migraine group
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showed poorer subjective performance at the onset of therapy,
both groups benefited equally from rehabilitation. The same
degree of improvement was observed in the migraine group
regardless of medication regime. This study suggested that vestibu-
lar rehabilitation therapy may be effective in vestibular migraine
regardless of the used medical prophylactic therapy (43). Even
though, this is in line with the very positive effect of physical activ-
ity on the reduction of migraine with and without aura, yet again, a
controlled study design is required in order to clearly recommend
such a therapy approach.
BEHAVIORAL MODIFICATION
One interesting study investigated the cessation of caffeine for
the treatment of vestibular migraine in 34 patients (44). Four-
teen percent of patients reported improvement in symptoms upon
caffeine cessation. In comparison, the same study showed that
topiramate reduced symptoms in 25% of patients and 46% of
patients reported a reduction in dizziness after nortriptyline ther-
apy (p= 0.007). In total, 75% of VM patients received sufficient
benefit from this therapeutic pathway to not progress to other
treatments (44).
RECOMMENDATIONS FOR TREATMENT
The treatment recommendations for vestibular migraine are cur-
rently similar to those for migraine with or without aura because
of the lack of specific trials in that field. Some of the following
treatment recommendations are based on the authors’ experience.
According to the available literature zolmitriptan 5 mg (tablet,
nasal spray, and dissolvable tablet) should be the first choice in
the acute vestibular migraine attack. Rizatriptan may also be used
and analogous to migraine any other triptan may be just as effec-
tive (45). Patients with excessive nausea or vomiting may prefer
non-oral applications (i.e., nasal spray, suppositories or subcuta-
neous injections) or intravenous options such as acetylsalicylacid
1000 mg where available with metoclopramide 10 mg or dimenhy-
drinate (62.5 mg). Prophylactic medications are not different from
treatment of migraine with or without aura and include propra-
nolol 80–240 mg, metoprolol 50–200 mg, bisoprolol 5–10 mg, or
flunarizine 5–10 mg per day in patients with over three attacks
per month, with very long lasting or disabling attacks, or fail-
ure to respond to acute treatment. Topiramate 25–100 mg and
valproic acid 500–600 mg may be used as well. Combination of
drugs belonging to the same class is probably not reasonable, and
the combination of topiramate with propranolol did not show
an additional benefit to topiramate alone (46). Patients with fre-
quent migraine attacks on 15 days per month for >3 months and
with >8 days with migraine headache per month for more than
3 months should receive topiramate 25–100 mg. A trial of onabot-
ulinumtoxin type A (155 MU), as used in the treatment of chronic
migraine, may also be reasonable, but this option is unlikely to
improve vestibular symptoms. Patients who predominantly com-
plain of vertigo or dizziness with typical aura duration,but without
frequent migraine headache might be successfully treated with
lamotrigine 25–100 mg per day (41).
CONCLUSION
So far there are no state-of-the-art published RCTs on the pro-
phylactic treatment of vestibular migraine. There is, however, an
ongoing multicenter randomized placebo-controlled trial (meto-
prolol 95 mg per day vs. placebo; the PROVEMIG-trial). Estab-
lished treatment regimens for migraine with and without aura
can be effective in vestibular migraine, but it remains uncertain
whether certain or more specific treatment options would be more
beneficial for this special patient group. The knowledge derived
from these clinical trials may also be useful for the distinction of
vestibular migraine from migraine with and without aura, as well
as from basilar-type migraine. Therefore, it could help to disen-
tangle whether vestibular symptoms are merely one of the many
migraine features or represent a genuine subform of migraine as
suggested by current terminology of vestibular migraine.
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